## TRICARE Prior Authorization Request Form for tralokinumab-LDRM (Adbry, Adbry Autoinjector)



## **USFHP Pharmacy Prior Authorization Form**

7231 Parkway Drive, Suite 100, Hanover, MD 21076

FAX Completed Form and Applicable Progress Notes to: (410) 424-4037

To be completed by Requesting provider			
Drug Name:	Strength:		
Dosage/Frequency (SIG):	Duration of Therapy:		

Questions? Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

Initial approvals expire after twelve months, renewal approvals are indefinite. For renewal of therapy an initial Tricare prior authorization approval is required.

	The state of the s						
Step	Please complete patient and physician information (please print):						
1	Patient Name: Physician	Physician Name:					
	Address: Ad	Address:					
	Sponsor ID #: Ph	Phone #:					
	Date of Birth Secure						
Step 2	Please complete the clinical assessment:						
	1. Has the patient received this medication under the TRICARE benefit in the last 6 months? Please choose "No" if the patient did not previously have a TRICARE approved PA for Adbry.	☐ Yes (subject to verification) Proceed to question 2	□ <b>No</b> Proceed to question 3				
	2. Has the patient's disease severity improved and stabilized to warrant continued therapy?	☐ Yes Sign and date below	□ No STOP Coverage not approved				
	3. For which indication is the requested medication being prescribed?	dermatitis - Proceed to que	oderate to severe or uncontrolled atopic titis - Proceed to question 4  ner - STOP Coverage not approved				
	4. Is the patient 12 years of age or older?	☐ Yes Proceed to question 5	□ No STOP Coverage not approved				
	5. Is the requested medication being prescribed by a dermatologist, allergist, or immunologist?	☐ Yes Proceed to question 6	□ No STOP Coverage not approved				

## TRICARE Prior Authorization Request Form for tralokinumab-LDRM (Adbry, Adbry Autoinjector)

	6.	Does the patient have a contraindication to, intolerability to, or have they failed treatment with ONE medication in EACH of the following two categories:  • topical corticosteroids –  o for patients 18 years of age or older: high potency/class 1 topical corticosteroids (such as, clobetasol propionate 0.05% ointment/cream, fluocinonide 0.05% ointment/cream) OR  o for patients 12 to 17 year of age: any topical corticosteroid AND  • topical calcineurin inhibitor (for example, tacrolimus, pimecrolimus)?	☐ Yes Proceed to question 7	□ No STOP Coverage not approved
	7.	Does the patient have a contraindication to, intolerability to, inability to access treatment, or have they failed treatment with Narrowband ultraviolet B (UVB) phototherapy?	☐ Yes Proceed to question 8	□ No STOP Coverage not approved
	8.	Is the patient taking any other immunobiologics (for example, benralizumab [Fasenra], mepolizumab [Nucala], or omalizumab [Xolair])	☐ Yes STOP Coverage not approved	□ No Sign and date below
Step 3	Ιc	ertify the above is true to the best of my knowledge	e. Please sign and date:	
		Prescriber Signature	Date	
				[10 July 2024]

For Internal Use Only				
Approved:	Duration of Approval:month(s)			
Denied:	Authorized By:			
☐ Incomplete/Other:	PA#:			
Date Faxed to MD:	Date Decision Rendered:			